NeoGenomics
Runs cancer diagnostic laboratories serving community oncologists, pathologists, and pharmaceutical trial sponsors.
Something off on this page? Send us feedback.
Profile
Operates a single-segment network of cancer diagnostics laboratories built through a decade of acquisitions, running cytogenetics, molecular, and liquid-biopsy tests for community oncologists and pathologists while also running contract testing for pharmaceutical sponsors of cancer trials. Revenue depends on payer reimbursement for genomic panels and channel penetration among community cancer practices.
Runs a network of cancer diagnostics laboratories assembled through a series of acquisitions — Clarient, Genoptix, Inivata, and Pathline among them — testing for cytogenetic, immunohistochemistry, flow cytometry, and next-generation-sequencing markers used in cancer diagnosis and monitoring. Clinical testing for community oncologists and pathologists sits alongside contract testing and data services for pharmaceutical companies running cancer trials, now managed as one reportable segment.
Laboratory operations concentrate in the United States, spanning Florida, California, Tennessee, Texas, and New Jersey, with a smaller international presence in Switzerland and the United Kingdom.
Growth depends on reimbursement from Medicare and commercial payers for genomic test panels and on expanding share among community cancer practices. The RaDaR minimal-residual-disease liquid-biopsy assay remains under a permanent injunction stemming from a competitor's patent infringement suit.
Company facts
Key statistics
Year to date +53.4% · Average volume (30d) 2.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 29, 2026 | Craig-Hallum | Reiterate | Buy | $19 | ||
| Apr 29, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform | $14 | $25 |
| Apr 29, 2026 | Benchmark | Upgrade | Hold | Buy | ||
| Feb 24, 2026 | Piper Sandler | Reiterate | Overweight | $11 | $13 | |
| Oct 28, 2025 | Leerink Partners | Target | $14 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026Q2 FY26 | $0.03 | $0.05 | +49.0% | $196.9M | $201.7M | +2.4% | +13.96% |
| Apr 28, 2026Q1 FY26 | $0.01 | $0.01 | +73.0% | $184.5M | $186.7M | +1.2% | −0.67% |
| Feb 17, 2026Q4 FY25 | $0.04 | $0.06 | +50.0% | $188.5M | $190.2M | +0.9% | −10.31% |
| Oct 28, 2025Q3 FY25 | $0.02 | $0.03 | +50.0% | $188.2M | $187.8M | −0.2% | +3.63% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $168.0M | $181.3M | $187.8M | $190.2M | $186.7M | $201.7M | |
| Gross profit | $73.2M | $77.3M | $80.4M | $75.7M | $80.9M | $91.9M | |
| Operating income | −$27.8M | −$47.6M | −$27.0M | −$11.1M | −$18.2M | −$9.8M | |
| Net income | −$25.9M | −$45.1M | −$27.1M | −$9.9M | −$17.1M | $2.2M | |
| Diluted EPS | −$1.00 | −$1.75 | −$1.05 | −$0.38 | −$0.65 | $0.10 | |
| Gross margin | 43.6% | 42.6% | 42.8% | 39.8% | 43.3% | 45.6% | |
| Operating margin | -16.6% | -26.3% | -14.4% | -5.9% | -9.8% | -4.8% |
Fiscal years (4-quarter sums)FY21 $484.3M · FY22 $509.7M · FY23 $591.6M · FY24 $660.6M · FY25 $727.3M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $145.5M · Total debt $448.4M · Total assets $1.35B · Shareholders' equity $785.7M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 25.70M · Float 23.31M · 90.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.87M | 81.22% | 13F | Aug 7, 2026 |
| First Light Asset Management, LLC | 12.28M | 47.79% | 13F | Aug 14, 2026 |
| First Trust Advisors LP | 10.11M | 39.36% | 13F | Aug 11, 2026 |
| First Trust Portfolios L.P. | 10.11M | 7.77% | 13G | Jul 30, 2026 |
| Greenhouse Funds LLLP | 8.57M | 33.37% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Greg D. Aunan | officer: Chief Accounting Officer | −20,000 | $16.07 |
| Jun 15, 2026 | Lynn A. Tetrault | director | −5,307 | $11.10 |
| Jun 9, 2026 | Lynn A. Tetrault | director | −5,307 | $11.29 |
| Jan 20, 2026 | Warren Stone | officer: Pres & Chief Operating Officer | −22,128 | $12.50 |
| Nov 25, 2025 | Alicia C. Olivo | officer: EVP, GC & Business Development | −20,916 | $12.00 |
Peers
- Natera
Dominant MRD rival — Signatera vs RaDaR, plus years of patent litigation
- Guardant Health
MRD, liquid biopsy, and pharma-data overlap via Guardant Reveal and Guardant360
- Tempus AI
Fast-growing NGS, liquid biopsy, and AI-driven pharma-data rival
- Labcorp
Much larger diversified lab and CRO with an oncology NGS and MRD testing arm
- Quest Diagnostics
Diversified national lab with a growing oncology and MRD testing arm
- Myriad Genetics
Narrower rival in hereditary cancer risk and tumor HRD companion diagnostics
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Myriad Genetics | $3.16 | +0.48% | $298.5M | — | — | 0.4 | −10.5% |
| Median | 26.7 | 19.5 | 5.1 | +15.9% |